Plain-English translation of NCT06719141 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help reduce seizures in children and adults with developmental and epileptic encephalopathies—a group of rare, serious epilepsy conditions. The study will compare the medication to a placebo (a pill with no active ingredient) to understand whether the treatment actually works and how safe it is. About 320 people will participate over approximately 24 months.
Children and adults with these rare, severe epilepsy conditions often have frequent seizures even while taking multiple current medications, and they urgently need new treatment options. This trial aims to find out whether the medication can safely help reduce these seizures.
If you join, you will be randomly assigned to receive either the new medication or a placebo. You'll gradually increase the dose during the first part of the study, then stay on a stable dose for several months, and finally taper off slowly. You'll visit the study clinic multiple times over about 24 months, and you'll keep a diary to track your seizures. The study team will monitor you closely for how well the medication works and any side effects.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States